120 related articles for article (PubMed ID: 26234247)
1. Peripheral Sympathetic Nerve Dysfunction in Adolescent Japanese Girls Following Immunization with the Human Papillomavirus Vaccine.
Hanley SJ; Pollock KG; Cuschieri K
Intern Med; 2015; 54(15):1953. PubMed ID: 26234247
[No Abstract] [Full Text] [Related]
2. Peripheral Sympathetic Nerve Dysfunction in Adolescent Japanese Girls Following Immunization with the Human Papillomavirus Vaccine.
Kinoshita T; Ikeda S
Intern Med; 2015; 54(15):1955. PubMed ID: 26234248
[No Abstract] [Full Text] [Related]
3. Human Papillomavirus (HPV) Vaccination: Just the Facts.
Kinoshita T; Ikeda S
Intern Med; 2015; 54(14):1831. PubMed ID: 26179548
[No Abstract] [Full Text] [Related]
4. Human Papillomavirus (HPV) Vaccination: Just the Facts.
Castle P; Konno R; Bosch X
Intern Med; 2015; 54(14):1829. PubMed ID: 26179547
[No Abstract] [Full Text] [Related]
5. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine.
Kinoshita T; Abe RT; Hineno A; Tsunekawa K; Nakane S; Ikeda S
Intern Med; 2014; 53(19):2185-200. PubMed ID: 25274229
[TBL] [Abstract][Full Text] [Related]
6. Consensus statement from 17 relevant Japanese academic societies on the promotion of the human papillomavirus vaccine.
Iwata S; Okada K; Kawana K;
Vaccine; 2017 Apr; 35(18):2291-2292. PubMed ID: 28325478
[No Abstract] [Full Text] [Related]
7. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
[TBL] [Abstract][Full Text] [Related]
8. Immunization update: pertussis, meningoccocus, and human papillomavirus.
Middleman AB
Adolesc Med Clin; 2006 Oct; 17(3):547-63; abstract ix-x. PubMed ID: 17030279
[TBL] [Abstract][Full Text] [Related]
9. Safety of the quadrivalent human papillomavirus vaccine.
Brotherton JM
BMJ; 2013 Oct; 347():f5631. PubMed ID: 24108153
[No Abstract] [Full Text] [Related]
10. Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.
Matsumoto K; Yaegashi N; Iwata T; Yamamoto K; Nagashima M; Saito T; Ushijima K; Takahashi F; Noda K; Yoshikawa H
Int J Cancer; 2017 Oct; 141(8):1704-1706. PubMed ID: 28657110
[No Abstract] [Full Text] [Related]
11. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
[TBL] [Abstract][Full Text] [Related]
12. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
13. Autoimmunity, Autonomic Neuropathy, and the HPV Vaccination: A Vulnerable Subpopulation.
Schofield JR; Hendrickson JE
Clin Pediatr (Phila); 2018 May; 57(5):603-606. PubMed ID: 28868890
[No Abstract] [Full Text] [Related]
14. Prevention of human papillomavirus infection: provisional recommendations for immunization of girls and women with quadrivalent human papillomavirus vaccine.
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2007 Sep; 120(3):666-8. PubMed ID: 17766541
[TBL] [Abstract][Full Text] [Related]
15. Two-dose schedule for human papillomavirus vaccine.
Baker H
Lancet Oncol; 2017 Jan; 18(1):e3. PubMed ID: 27916396
[No Abstract] [Full Text] [Related]
16. Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events.
Callréus T; Svanström H; Nielsen NM; Poulsen S; Valentiner-Branth P; Hviid A
Vaccine; 2009 May; 27(22):2954-8. PubMed ID: 19428906
[TBL] [Abstract][Full Text] [Related]
17. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
[TBL] [Abstract][Full Text] [Related]
18. Safety and success of the human papillomavirus vaccine: time for a robust vaccination program in the United States and worldwide.
Duska LR
Clin Ther; 2014 Jan; 36(1):4-7. PubMed ID: 24417780
[No Abstract] [Full Text] [Related]
19. Safety of Human Papillomavirus Vaccines: An Updated Review.
Phillips A; Patel C; Pillsbury A; Brotherton J; Macartney K
Drug Saf; 2018 Apr; 41(4):329-346. PubMed ID: 29280070
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
